Literature DB >> 18410431

Phosphodiesterase type 5 inhibitors in the management of erectile dysfunction secondary to treatments for prostate cancer: findings from a Cochrane systematic review.

Bridget Candy1, Louise Jones, Rachael Williams, Adrian Tookman, Michael King.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18410431     DOI: 10.1111/j.1464-410X.2008.07668.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  6 in total

Review 1.  Vardenafil orodispersible tablet.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2012-01-01       Impact factor: 9.546

2.  Effects of intravenous injection of adipose-derived stem cells in a rat model of radiation therapy-induced erectile dysfunction.

Authors:  Xuefeng Qiu; Jacqueline Villalta; Ludovic Ferretti; Thomas M Fandel; Maarten Albersen; Guiting Lin; Yutian Dai; Tom F Lue; Ching-Shwun Lin
Journal:  J Sex Med       Date:  2012-04-30       Impact factor: 3.802

Review 3.  Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy.

Authors:  Xiao Wang; Xinghuan Wang; Tao Liu; Qianwen He; Yipeng Wang; Xinhua Zhang
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

Review 4.  Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.

Authors:  Wen-Hao Zhang; Xin-Hua Zhang
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

Review 5.  Penile prosthesis in the management of erectile dysfunction following cancer therapy.

Authors:  Pranav Dadhich; Mark Hockenberry; E Will Kirby; Larry Lipshultz
Journal:  Transl Androl Urol       Date:  2017-11

6.  Development of UK guidance on the management of erectile dysfunction resulting from radical radiotherapy and androgen deprivation therapy for prostate cancer.

Authors:  I D White; J Wilson; P Aslet; A B Baxter; A Birtle; B Challacombe; J Coe; L Grover; H Payne; S Russell; V Sangar; N Van As; M Kirby
Journal:  Int J Clin Pract       Date:  2014-10-06       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.